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Abstract 
Background: Mucosal HIV-1 transmission predominantly results in a single transmitted/founder (T/F) virus establish-
ing infection in the new host despite the generally high genetic diversity of the transmitter virus population. To what 
extent HIV-1 transmission is a stochastic process or driven by selective forces that allow T/F viruses best to overcome 
bottlenecks in transmission has not been conclusively resolved. Building on prior investigations that suggest HIV-1 
envelope (Env) features to contribute in the selection process during transmission, we compared phenotypic virus 
characteristics of nine HIV-1 subtype B transmission pairs, six men who have sex with men and three male-to-female 
transmission pairs.
Results: All recipients were identified early in acute infection and harbored based on extensive sequencing analysis a 
single T/F virus allowing a controlled analysis of virus properties in matched transmission pairs. Recipient and trans-
mitter viruses from the closest time point to transmission showed no signs of selection for specific Env modifications 
such as variable loop length and glycosylation. Recipient viruses were resistant to circulating plasma antibodies of 
the transmitter and also showed no altered sensitivity to a large panel of entry inhibitors and neutralizing antibodies. 
The recipient virus did not consistently differ from the transmitter virus in terms of entry kinetics, cell–cell transmis-
sion and replicative capacity in primary cells. Our paired analysis revealed a higher sensitivity of several recipient 
virus isolates to interferon-α (IFNα) which suggests that resistance to IFNα cannot be a general driving force in T/F 
establishment.
Conclusions: With the exception of increased IFNα sensitivity, none of the phenotypic virus properties we investi-
gated clearly distinguished T/F viruses from their matched transmitter viruses supporting the notion that at least in 
subtype B infection HIV-1 transmission is to a considerable extent stochastic.
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Background
The identification of host and viral determinants that 
govern human immunodeficiency virus type 1 (HIV-
1) transmission and infection is essential for the 
development of a targeted prevention approach. The 
observation that virus populations in acute infection are 
very homogeneous [1–4] contrasting the high diversity 
of the HIV-1 quasispecies observed in chronic infection 
[5] suggested that HIV-1 encounters a population bot-
tleneck upon transmission (reviewed in [6, 7]). This was 
further corroborated by the discovery that the majority 
of transmitted viruses are CCR5 utilizing (R5 tropic) [1, 
8, 9], although later during natural history of the infec-
tion a tropism switch to CXCR4 co-receptor utilizing (X4 
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tropic) HIV-1 variants occurs in untreated infection in 
approximately 50 % of individuals [10]. Early findings that 
only few viral variants are transmitted and seed a new 
infection were substantiated by single genome amplifi-
cation (SGA) approaches which revealed that depending 
on the mode of sexual transmission, in 60–90 % of cases 
a single HIV-1 variant [termed the transmitted/founder 
(T/F) virus], establishes an infection [11–15]. These find-
ings funneled intensive research efforts aiming to under-
stand if the limited transmission of viral variants is due 
to selective forces acting during transmission and early 
infection or is simply the result of a stochastic process 
(reviewed in [6, 7]).
A potential influence of genotypic and phenotypic 
traits of the HIV-1 envelope (Env) in steering transmis-
sion was first suggested in a study of eight heterosexual 
HIV-1 subtype C transmission pairs [16]. Recipient Envs 
had shorter V1–V4 loops with less potential N-linked 
glycosylation sites (PNGS) and showed increased sensi-
tivity to the corresponding transmitter’s plasma. Reduced 
length and glycosylation of Env proved a trait in HIV-1 
subtype A, C and D, and possibly also in subtype B trans-
mission [17–23]. Less clear is the influence of neutrali-
zation sensitivity on transmission and variable patterns 
of T/F virus sensitivity to monoclonal antibodies and 
transmitter’s plasma were observed in subtype B and C 
infection [11, 19, 20, 24–26]. T/F viruses proved equally 
efficient as corresponding transmitter or chronic control 
viruses in establishing CD4 and CCR5 receptor interac-
tions [20, 24, 27–29] and macrophage tropism appears 
not to be associated with transmission as T/F viruses 
efficiently infect CD4+ T-cells but not monocyte-derived 
macrophages (MDMs) [28, 30, 31]. Furthermore, acute 
Envs have been suggested to bind the integrin α4β7 
with high affinity [29, 32, 33]. T/F infectious molecular 
clones of HIV-1 subtype B and C were, when compared 
to chronic control viruses more infectious, harbored 
more Env, and bound to dendritic cells more efficiently 
[34]. Additionally, T/F viruses were reported to be more 
resistant to interferon-α (IFNα) as compared to chronic 
stage viruses from the same or control individuals raising 
the possibility that IFNα resistance may aid these viruses 
to evade early immune responses [34, 35]. Interestingly, a 
study in injection drug users of HIV-1 subtype B as well 
as a recent publication investigating six HIV-1 subtype 
C transmission pairs could not reproduce higher IFNα 
resistance of acute viruses [26, 36].
While CCR5 tropism is clearly selected for in trans-
mission, not all viral properties described as selective 
parameters during transmission are consistently linked 
with T/F viruses across different studies. This may in 
part be due to differences in the population bottleneck 
that might vary depending on the HIV-1 subtype and 
the transmission mode studied. Differences between the 
transmitter and T/F viruses may also be very subtle and 
their identification may thus depend on studying defined 
transmission pairs where viruses were derived at time 
points very close to the transmission date. Not all studies 
on the in vitro phenotyping of T/F viruses described to 
date had access to the optimal transmitter viruses: Often 
transmitters are not known, which restricted the com-
parison to unrelated chronic control viruses. Consider-
ing the high variability of the HIV-1 Env and that minor 
sequence changes can have a considerable impact on Env 
functionality cross-sectional analysis alone may not suf-
fice to define selective forces of transmission. We there-
fore thought it crucial to perform a paired analysis of 
confirmed transmission pairs to investigate the influence 
of Env traits in the transmission process. We investigated 
in total nine HIV-1 subtype B transmission pairs that we 
phylogenetically identified within the Zurich Primary 
HIV Infection (ZPHI) study and the Swiss HIV Cohort 
Study (SHCS). In six pairs HIV was acquired through 
men who have sex with men (MSM) transmission and 
in three pairs through male-to-female (MTF) transmis-
sion. We analyzed phenotypic properties of transmitter 
and recipient viruses with a particular focus on Env to 
define if T/F viruses harbor distinct features that are cru-
cial during the earliest stages of HIV-1 infection endow-
ing viruses with a transmission advantage. Based on the 
investigated phenotypic virus properties, our findings 
suggest that at least in subtype B infection HIV-1 trans-
mission is to a considerable extent stochastic.
Results
Large‑scale phylogenetic analysis of polymerase sequences 
in two Swiss HIV cohorts identifies linked transmission 
pairs
A paired analysis of viruses from confirmed transmission 
pairs is key to understand the selective forces in HIV-1 
transmission. To identify transmission pairs amongst 
individuals enrolled in the ZPHI study and the SHCS 
we utilized polymerase (pol) sequences derived from 
genotypic resistance tests in a phylogenetic analysis [37]. 
The ZPHI study is a prospective, observational, single 
center cohort enrolling patients with a confirmed acute 
or recent primary HIV-1 infection [37–39]. The SHCS 
is a nationwide cohort incorporating all HIV-1 infected 
adults living in Switzerland and includes at least 53 % of 
all HIV infections ever diagnosed in Switzerland [40, 41].
By subjecting 508 pol sequences from 300 ZPHI 
patients and 23,705 pol sequences from over 19,000 
SHCS patients to phylogenetic analysis we were able to 
identify probable transmission pairs. Pairs with a genetic 
distance in pol of <1.5  % (Additional file  1: Figure S1a) 
were further examined [37]. We defined the estimated 
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date of transmission (EDT) by incorporating available 
information of recipients on previous HIV tests, West-
ern blot results, avidity assays, the start of acute retro-
viral symptoms and potential risk situations [37–39]. 
Additionally, we took clinical and epidemiological data 
of potential transmitters at the EDT such as viral load, 
antiretroviral treatment and risk group into account for 
determining transmission pairs and of three pairs, trans-
mitters disclosed that they had infected corresponding 
recipients. To confirm virus transmission, we selected 
transmitter and recipient plasma from the biobanks of 
the ZPHI and the SHCS from the closest possible time 
point to transmission to perform SGA of full-length env. 
Of note, although a greater number of transmission pairs 
was identified with this iterative analysis involving phy-
logenetic data of pol and env and the available patients’ 
history, we focused here on studying nine HIV-1 subtype 
B transmission pairs (transmitter T8 is a subtype B/F1 
recombinant) as for these bio bank samples for follow-
up experiments were available. Of the nine transmission 
pairs studied, six recipients acquired HIV-1 via MSM and 
three recipients via MTF transmission. In total, 174 SGA 
env sequences of transmitters and recipients from those 
nine transmission pairs were derived and used to confirm 
transmission pair linkage by env phylogenetic analysis 
and to define T/F populations in the assumed recipients 
(Additional file 1: Figure S1b). The recipients were iden-
tified and sampled after a median duration of 49  days 
(range 26–90  days) after EDT confirming the status of 
early infection (Table  1). Available samples of transmit-
ters were within a median time interval of 57 days of the 
EDT (range −20 to 170  days; Table  1; Additional file  2: 
Figure S2). Four out of the nine transmitters had a rela-
tively low viral diversity (env diversity  <  1  %). One of 
these individuals was recently infected and two others 
had started antiretroviral treatment immediately after 
infection and transmitted HIV-1 upon virus rebound 
after structured treatment interruption (Table  2). As 
most prior studies focused on high diversity transmis-
sion we considered it important to include low diversity 
cases as well in our study as acutely infected transmitters 
account for a large proportion of new infections [42–44]. 
Furthermore, although high virus diversity will provide 
more opportunity for selection processes, low diversity 
transmission pairs where transmitter and recipient have 
high sequence similarity may allow more ready detec-
tion of genotypes and phenotypes that develop early after 
infection and which are essential for transmission.
Sequence characteristics of transmitter and recipient 
viruses
To enable phenotypic comparison of the env gene of 
transmitter and recipient viruses we performed compari-
sons with virus isolates and Env pseudotyped viruses. All, 
the virus isolate, the cloned full length envs and the env 
SGA analysis were derived from the closest possible time 
points to the EDT. Virus isolates of recipients and trans-
mitters were derived from peripheral blood mononuclear 
cells (PBMCs) by co-culture with CD8-depleted PBMCs 
from HIV-1 negative donors. Full length Env clones 
were isolated from plasma from the same time point 
the SGA analysis was performed and from virus isolates 
derived from exactly this time point (Additional file  2: 
Figure S2). Cloned env sequences tightly clustered with 
env sequences derived from SGA (Fig. 1) and with next 
generation sequencing data from plasma and virus iso-
lates (Additional file  3: Figure S3). Recipient Env clones 
selected for further characterization closely matched the 
Table 1 Patients’ and virus’ characteristics of HIV-1 subtype B infected transmission pairs
T transmitter, R recipient, MSM men who have sex with men, HET heterosexual, MTF male-to-female
a Time from the EDT to the day of sample collection. Negative value means sample was collected before EDT
b HIV-1 RNA copies/ml of plasma at the day of sample collection
c CD4+ T cells/μl at the day of sample collection
Pair Transmission mode Virus tropism Interval (days)a Viral loadb CD4 countc
T R T R T R T R
T1–R1 MSM R5 R5 95 32 153,000 2,325,000 287 273
T2–R2 HET (MTF) R5 R5 49 42 18,300 412,857 416 625
T3–R3 MSM R5X4 R5 170 84 34,600 14,400 115 656
T4–R4 HET (MTF) R5 R5 57 43 9813 66,000 681 346
T5–R5 MSM R5 R5 −20 26 43,200 373,000 422 430
T6–R6 HET (MTF) R5 R5 63 49 257,532 428,000 623 170
T7–R7 MSM R5 R5 33 61 2830 5,970,000 595 362
T8–R8 MSM R5 R5 3 56 2260 56,300 664 564
T9–R9 MSM R5 R5 89 90 27,800 1550 429 516
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respective consensus SGA sequences. The Env clones 
were identical to the respective recipient SGA consensus 
sequence in three cases, had one amino acid mismatch 
in three cases, two amino acid mismatches in two cases 
and three amino acid mismatches in one case (Additional 
file  4: Figure S4). Of note, in two recipients the cloned 
Envs contained mismatches that were identical to a SGA 
variant and were found as a variant in corresponding 
transmitters. As expected in established infection, trans-
mitter sequences had a considerable heterogeneity. Based 
on an extensive sequence and phylogenetic analysis we 
selected virus Env clones that reflect the diversity seen 
in transmitters and were also functional in supporting 
virus entry. The selected clones are indicated in Fig. 1 and 
Additional file 4: Figure S4.
In total, we included for each recipient a single Env 
clone and for transmitters one to three different Env 
clones in the subsequent Env-pseudovirus analysis 
(Fig.  1; Additional file  3: Figure S3; Additional file  4: 
Figure S4). All selected Env clones were functional as 
defined by Env-pseudovirus infection of TZM-bl cells. 
We next compared the infectivity of transmitter and 
recipient viruses by measuring the infectivity of serial 
dilutions of pseudovirus stocks on TZM-bl cells. Activity 
of the luciferase reporter measured as relative light units 
(RLU) per μl input of the respective virus stocks was 
recorded. The infectivity varied both amongst transmit-
ters (101–4637 RLU/μl virus stock input) and recipients 
(46–5752  RLU/μl virus stock input) but was not statis-
tically different across the two groups (p  =  0.496; Wil-
coxon matched-pairs signed rank test).
The comparison of next generation sequencing data 
from virus isolates and, if available, plasma virus to the 
SGA consensus of recipients revealed that the retrieved 
virus isolates and Env clones were indeed representa-
tive of the patients virus populations. In six recipients 
the haplotype was identical to the SGA consensus, in 
two recipients the haplotypes contained mismatches 
that were also found in SGA and clonal sequences and 
in one recipient with three haplotypes the major haplo-
type was identical to the SGA consensus. In transmitters 
the haplotypes found in virus isolates and plasma closely 
matched the SGA and clonal sequences showing that our 
virus isolates represent the circulating virus population 
in vivo.
To obtain a comprehensive picture of the virus popula-
tions of transmitters and recipients at the EDT we com-
piled all env sequences retrieved by SGA and cloning in a 
genetic analysis. Recipient sequences proved very homo-
geneous and formed a monophyletic sub-cluster within 
their corresponding transmitter sequences (for high 
diversity transmitters) highly suggesting that the recipi-
ents were infected by a single T/F virus in all nine pairs 
we investigated (Fig.  1; Additional file  3: Figure S3). In 
line with this, recipients had a significantly lower genetic 
diversity in env (median 0.18 %, range 0.07–0.35 %) com-
pared to transmitters (median 1.08 %, range 0.34–4.61 %; 
p = 0.004; Table 2).
As length and glycosylation of Env variable loops have 
been implicated as selecting features in transmission 
[16–18, 22] we compared these domains across transmis-
sion pairs. Although differences in length and glycosyla-
tion were apparent in the V1V2 and V4 domains, there 
was no consistent trend in recipients towards reduction 
in length (p = 0.854 for V1V2 and p = 0.713 for V4) or 
glycosylation (p = 0.346 for V1V2 and p = 0.233 for V4; 
Additional file  5: Table S1). Two motifs, the presence 
of a Histidine at position 12 in the Env leader peptide 
Table 2 Pairwise pol distance, env population distance and diversity along with infection stage of transmission pairs
T transmitter, R recipient
a Sequences of T9 are derived from full-length env clones only after several SGA attempts failed
b  Early antiretroviral treatment (eART) was started immediately after infection and HIV-1 was transmitted upon virus rebound after structured treatment interruption 
(STI)
Pair pol distance (%) No. of env sequences env distance (%) env diversity (%) Infection stage
T R T R T R
T1–R1 0.24 28 23 1.45 3.05 0.26 Chronic Acute
T2–R2 0.48 21 27 2.45 4.61 0.18 Chronic Acute
T3–R3 0.71 20 11 1.49 3.37 0.10 Chronic Acute
T4–R4 0.48 30 10 0.85 1.69 0.07 Chronic Acute
T5–R5 0.23 18 19 0.28 0.93 0.22 Chronic Acute
T6–R6 0.24 25 18 0.11 0.51 0.34 Recent Acute
T7–R7 0.15 5 18 0.12 0.34 0.12 eART-STIb Acute
T8–R8 0.08 17 19 0.32 0.50 0.11 eART-STIb Acute
T9–R9 0.16 5a 8 1.40 1.08 0.35 Recent Acute
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associated with increased Env expression and infectivity, 
and the loss of a PNGS site in V4 (HXB2 position 413–
415) whose presence is associated with neutralization 
escape, have previously been associated with acute infec-
tion [45, 46]. Additionally, acute viruses have been shown 
to bind with a higher affinity to the α4β7 integrin via a 
tripeptide motif in V2, most commonly Leucine-Aspar-
tic acid-Isoleucine/Valine (HXB2 position 182–184) [32, 
33, 47]. A comparison of transmitter and recipient Env 
sequences in our study did not link any of the described 
Fig. 1 Linkage of envelope sequences from HIV-1 transmission pairs. Maximum likelihood phylogenetic trees of full-length env sequences from 
transmitters (red) and recipients (blue). Sequences derived from single genome amplification are displayed with filled circles and those inferred from 
cloning with open circles. Triangles depict sequences that were used as Env-pseudoviruses for follow-up experiments. Arrows indicate the most 
recent common ancestors (MRCA). Branch lengths are drawn to scale and HIV-1 HXB2 was used as a subtype B reference. For highlighter plots with 
all sequences see Additional file 4: Figure S4
Page 6 of 20Oberle et al. Retrovirology  (2016) 13:62 
motifs with transmission as none of them were over- or 
underrepresented in recipient viruses (Additional file  5: 
Table S1).
Previously it was suggested that T/F viruses might har-
bor a more ancestral genotype as evidenced by shorter 
distances of T/F viruses to the most recent common 
ancestor (MRCA) [18, 48]. In six out of nine transmission 
pairs (T1–R1, T2–R2, T3–R3, T6–R6, T7–R7 and T9–
R9) we found shorter distances of recipient env sequences 
to the MRCA as compared to transmitter sequences 
(Fig. 1, Additional file 6: Table S2). However, when per-
forming a Wilcoxon matched-pairs signed rank test using 
the distances to the MRCA, we observed neither a statis-
tical difference across all transmitter and recipient pairs 
(p  =  0.129) nor when focusing on the pairs with high 
virus diversity (p = 0.188).
Concurrent plasma antibodies of transmitters fail 
to neutralize transmitter and recipient viruses
Sensitivity to neutralization has been considered a com-
mon property among transmitted virus variants [16]. To 
explore the neutralization sensitivity of transmitter and 
recipient Env-pseudoviruses, we examined the neutrali-
zation capacity of transmitter and recipient plasma in 
TZM-bl Env-pseudovirus assays. As expected, recipi-
ents’ plasma at the EDT displayed no noteworthy neu-
tralization capacity as the plasma samples were all close 
to the EDT and an autologous neutralization response 
had not yet evolved (n = 8; Fig. 2a, b). Importantly, how-
ever, transmitter plasma from time points before the 
EDT (n = 4) and from the closest time point to the EDT 
(n  =  7) neither neutralized the autologous nor recipi-
ent virus (Fig.  2a, b). At the highest plasma concentra-
tion tested, the seven probed transmitter plasma samples 
derived from the closest time point to the EDT showed 
only low level neutralization activity against the corre-
sponding recipient and transmitter viruses in line with 
the expected neutralization escape in the transmitter. Of 
note, in five cases recipient viruses were slightly more 
neutralization sensitive than the corresponding transmit-
ter viruses, however no consistent difference in neutrali-
zation sensitivity was observed between transmitter and 
recipient Envs (p = 0.297; Additional file 7: Figure S5).
To obtain an overall estimate of the neutralization 
capacity of the probed transmitter plasma samples we 
analyzed their activity against the Tier-1 HIV-1 isolate 
SF162 (Fig.  2c). Transmitter plasma samples from time 
points before the EDT neutralized SF162 only in one 
out of four cases recapitulating the early infection stage 
of individuals T5, T7 and T8. A basic neutralization 
response was established at later time points in all trans-
mitters as all transmitter plasma samples from the EDT 
effectively neutralized SF162 (50  % neutralization titer 
(NT50) ranging from 103 to 1017; Fig. 2c). This indicates 
the presence of neutralizing antibodies in the transmitter 
plasma at the EDT to which the contemporaneous recipi-
ent virus is not sensitive (NT50 SF162 vs. recipient or 
transmitter virus p = 0.016). In contrast, recipient plasma 
samples, as expected, failed at the time point of trans-
mission to neutralize SF162. The exception was patient 
R9 who neutralized SF162 with relatively high potency 
(NT50  =  363) indicating an early neutralizing antibody 
response in this individual (Fig.  2c). As expected most 
Fig. 2 Transmitter and recipient viruses are resistant to plasma 
neutralizing antibodies of transmitters circulating at transmission. 
The 50 % neutralization titer (NT50, i.e., the reciprocal plasma dilu-
tion yielding 50 % neutralization) for a transmitter, b recipient and 
c SF162 Env-pseudoviruses against transmitter (red) and recipient 
(blue) plasma samples, respectively. Off-antiretroviral treatment (ART) 
plasma samples tested were from time points before the estimated 
date of transmission (EDT) (only for transmitter plasma), closest to 
the EDT or after the EDT. Due to differences in ART initiation and 
limitations in sample availability, plasma sample time points and virus 
combinations are not identical for each probed individual. NT50 val-
ues were derived from 2 independent experiments each performed 
in duplicates. SF162 was included as a Tier-1 neutralization sensitive 
virus. The dotted line indicates the threshold for NT50 determination as 
the highest plasma concentration tested was 1:40 and values below 
the threshold were given an arbitrary value of 30. For detailed NT50 
values and for plasma sample time points see Additional file 8: Table 
S3 and Additional file 2: Figure S2, respectively
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plasma samples of transmitters and recipients derived at 
time points after the EDT improved neutralization activ-
ity against the transmitter and recipient viruses derived 
at the EDT and also more potently neutralized SF162 
(Fig. 2).
Comparable sensitivity of transmitter and recipient viruses 
to neutralizing antibodies and entry inhibitors
Although sensitivity of recipient and transmitter viruses 
to the autologous and transmission partner plasma anti-
bodies did not differ, this does not allow drawing gen-
eral conclusions on the neutralization sensitivity of the 
respective strains, as this solely reflects that the probed 
viruses largely had escaped contemporaneous autologous 
neutralization activity. We thus performed a comprehen-
sive assessment of the neutralization sensitivity of the 
recipient and transmitter viruses against a panel of neu-
tralizing antibodies and entry inhibitors in TZM-bl Env-
pseudovirus assays. We included in our inhibitor panel 
CD4 binding site directed agents (CD4-IgG2, VRC01, 
b12 and b6), the monoclonal antibody 2G12 that targets 
a carbohydrate motif in gp120, V3 directed antibod-
ies (PGT121, PGT128 and 1.79) and three gp41 specific 
inhibitors (T-20, 2F5 and 4E10). In sum, transmitter and 
recipient viruses disclosed moderate sensitivity to the 
inhibitor panel tested (Fig. 3a, Additional file 9: Table S4). 
Furthermore, although differences in sensitivity between 
individual transmitter and recipient Env-pseudoviruses 
existed, we found no evidence for an overall pattern of 
neutralization sensitivity that was segregating recipient 
from transmitter viruses (Fig. 3a).
Enhanced replicative capacity is not required 
for transmission
It has been considered for long that viruses that are suc-
cessfully transmitted may have distinguishing properties 
such as an improved access to target cells in the genital 
tract (reviewed in [49]). We indirectly assessed the effi-
cacy of the transmitter and recipient Env-pseudoviruses 
to infect cells at low CD4 and CCR5 levels by measuring 
their sensitivity to the CD4 specific inhibitor DARPin 
27.2 and the CCR5 antagonist Maraviroc. Sensitivity to 
CD4 (p = 0.129) and CCR5 (p = 0.652) blocking was very 
similar across viruses from transmitters and recipients 
(Fig. 3b, Additional file 9: Table S4).
To address target cell preference more directly, we 
next probed the infectivity of the transmitter and recipi-
ent virus isolates on primary CD4+ T-cells (PBMCs) and 
MDMs. A difference between these prototypic target 
cells of HIV-1 is the CD4 receptor density with CD4+ 
T-cells exhibiting approximately 20-fold higher CD4 den-
sities than MDMs [50]. In order to limit the influence of 
Fig. 3 Transmitter and recipient viruses exhibit no difference in sensitivity to neutralizing antibodies and entry inhibitors. Inhibition of transmitter 
and recipient Env-pseudoviruses by a gp120 directed, gp41 directed and b cell directed inhibitors in TZM-bl assays. Transmitter (T) and recipient (R) 
50 % inhibitory concentration (IC50) values in μg/ml are depicted and IC50 values above the highest concentration tested (indicated by the dotted 
line) were given an arbitrary value of 30. Transmission pairs are connected with a line. N specifies the number of Env-pseudoviruses (out of 26) with 
an IC50 value below the highest inhibitor concentration tested and the p values were determined by the Wilcoxon matched-pairs signed rank test. 
Values were derived from 2 independent experiments each performed in duplicates. For detailed IC50 values see Additional file 9: Table S4
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donor variability in the readout, we probed the entire 
virus panel on two pools of stimulated PBMCs of three 
donors each and titrated each virus isolate in parallel in 
the same experiment. To derive a measure for the repli-
cative capacity of individual strains we quantified virus 
replication by p24 antigen production and determined 
the area under the curve (AUC) over the entire 14  day 
observation period. A paired analysis of the derived 
median AUC revealed no significant differences between 
the transmitter and recipient viruses (p = 0.164; Fig. 4a). 
Alternative approaches to evaluate the replication fitness 
confirmed this (Additional file 10: Figure S6). To allow a 
comparison across transmission pairs we next calculated 
for each pair the ratio of recipient relative to transmitter 
AUC (Fig. 4b). These ratios showed a similar pattern with 
most recipients replicating at comparable levels relative 
to their transmitter in the two independent experiments. 
Transmission pairs T4–R4 and T5–R5 were the only 
two cases where the recipient viruses had a higher AUC 
on both donor pools (recipient AUC 8–39 % higher). In 
five transmission pairs, the recipient virus had a lower 
AUC than the corresponding transmitter (recipient AUC 
13–44 % lower).
To probe the capacity of the viruses isolated from the 
transmission pairs to infect MDMs we compared their 
replicative capacity on MDM preparations from twelve 
different donors as susceptibility to infection is known 
to vary substantially. In sum, we noted no general pat-
tern for preferential replication in MDMs by transmit-
ter or recipient virus isolates (p = 0.359; Fig. 4c). Despite 
the high donor variability of MDMs we observed a con-
gruent pattern: In five pairs recipient viruses proved 
to have a higher replicative capacity on MDMs and in 
four pairs the transmitter virus showed equal (T3–R3 
and T8–R8) or higher (T1–R1 and T4–R4) infection of 
MDMs (Fig. 4d). High replicative capacity on PBMCs and 
MDMs was not always linked. Transmitter T1 as well as 
recipient R5 had higher activity than their transmission 
partners both on PBMCs and MDMs, whereas for other 
pairs higher infectivity on one cell type was associated 
with a lower infectivity on the other (T2–R2, T4–R4 and 
T9–R9).
Fig. 4 Transmitter and recipient viruses show no significant difference in replicative capacity in PBMCs and MDMs. Replicative capacity of transmit-
ter and recipient virus isolates in CD8-depleted PBMCs and monocyte-derived macrophages (MDMs). Replicative capacity was quantified as area 
under the curve (AUC) of p24 antigen production in culture supernatants over a 14 day period. a, c Median AUCs for 2 PBMC pools and 12 MDM 
donors between transmitter and recipient viruses were tested for statistical significance with a Wilcoxon matched-pairs signed rank test. b, d AUCs 
of recipient virus isolates expressed relative to their corresponding transmitter virus isolate. Values above and below the dotted line indicate when 
recipient viruses have a higher and lower replicative capacity, respectively. Independent experiments are indicated by different symbols
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Entry kinetics of transmitter and recipient viruses match 
closely
A potential step where selection of recipient viruses 
may occur is the entry process. Viruses that are capa-
ble of completing entry more efficiently may have an 
advantage in establishing infection. To probe this, we 
assessed the entry kinetics of transmitter and recipient 
Env-pseudoviruses using a time-of-inhibitor addition 
experiment on TZM-bl cells [51]. In this assay, infec-
tion is synchronized through spinoculation and initial 
infection arrest at 10  °C and therefore allows for the 
assessment of virus entry kinetics at the steps post-
attachment but not during attachment. Infection is ini-
tiated upon temperature increase to 37 °C and blocked 
at different time points by addition of the fusion inhibi-
tor T-20 (Fig.  5a). By normalizing data points to the 
relative infectivity reached after 120  min and plot-
ting entry kinetic curves (Fig.  5b), the time to attain 
50  % entry was determined for each Env-pseudovirus 
tested. Time to 50  % entry ranged for transmitters 
from 12 to 58 min and for recipients from 14 to 52 min 
(Additional file  11: Figure S7), and the medians were 
similar between both groups (Fig.  5c). We observed a 
significant negative association between the time to 
50 % entry and the T-20 50 % inhibitory concentration 
(IC50; r2 =  0.31, p =  0.003), indicating that the fusion 
inhibitor benefits from slow entry kinetics likely as this 
widens its window of action (Fig. 5d).
Transmitter and recipient viruses are not distinguished 
by their cell–cell transmission and free virus infection 
capacity
A further phenotype that might endow recipient viruses 
with a transmission benefit is a higher efficacy for HIV-1 
cell–cell transmission and/or free virus infection. To 
compare both entry modes between transmitter and 
recipient Env-pseudoviruses, we used 293-T cells as 
donor cells and assessed cell–cell and free virus infection 
of A3.01-CCR5 target cells as in previously described 
protocols [52, 53]. Our data showed that in most trans-
mission pairs the pattern of infectivity in cell–cell and 
free virus transmission was concordant. Furthermore, 
recipient and transmitter viruses displayed variable cell–
cell and free virus infection capacities. When we com-
pared median values of transmitters to values of recipient 
viruses, neither cell–cell transmission (p = 0.055; Fig. 6a) 
nor free virus infection capacity (p = 0.301; Fig. 6b) was 
consistently different between transmitter and recipient 
viruses.
Recipient viruses are more sensitive to IFNα
Resistance to IFNα induced antiviral defenses has been 
postulated to steer the foundation of recipient viruses 
[34, 35]. Two other studies however, could not reproduce 
higher IFNα resistance of acute viruses [26, 36].
To clarify if IFNα resistance is a property that provides 
selective advantage during transmission, we analyzed 
Fig. 5 Transmitter and recipient viruses show comparable entry kinetics. a Scheme of time-of-inhibitor addition experiment on TZM-bl cells. b 
Entry kinetic curves for one representative transmission pair with two transmitter Env-pseudoviruses depicted in red and the recipient Env-pseu-
dovirus in blue. The relative infectivity reached after 120 min was set as 100 % and data points were normalized to this value. Data points are mean 
and standard deviation from three independent experiments each performed in duplicates. c Time to 50 % entry was determined out of entry 
kinetic curves and median time to 50 % entry of transmitter Env-pseudoviruses was compared to recipient Env-pseudoviruses applying a Wilcoxon 
matched-pairs signed rank test. d Linear regression analysis of T-20 IC50 and time to 50 % entry with r
2 and p value depicted. Data for transmitters 
and recipients are indicated in red and blue, respectively
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virus isolates from transmitters and recipients for their 
sensitivity to IFNα in in  vitro infection experiments of 
PBMCs. To account for the high variability in PBMC 
infectivity, we determined the 50 % tissue culture infec-
tious dose (TCID50) of all virus isolates on the same 
donor PBMCs and performed the experiment on four dif-
ferent PBMC pools. Assessment of the influence of type I 
IFN on HIV-1 infectivity necessitates a tightly controlled 
system as the effect of IFN is relatively modest and even 
small differences in virus input can result in substantially 
different accuracies in the estimation of IFNα activity as 
shown for the transmission pair T6-R6 (Fig. 7a). In line 
with this we observed a strong association between rep-
licative capacity in the absence and in the presence of 
IFNα (Additional file  12: Figure S8). We estimated the 
AUC over the entire observation period and determined 
the IFNα resistance defined as the percentage of repli-
cation (AUC) in the presence of IFNα compared to the 
untreated control. While we observed variation due to 
donor cell variability (Fig. 7b) the overall picture proved 
very coherent. In contrast to previous observations [34, 
35] the median IFNα sensitivity proved to be higher for 
recipient viruses than their paired transmitter viruses in 
our cohort (p  =  0.027) (Fig.  7c), suggesting that resist-
ance to IFNα was not decisive for the establishment of 
recipient viruses. Of note, across the nine transmission 
pairs investigated, we found no association between the 
sensitivity to IFNα mediated restrictions and the replica-
tive capacity of virus isolates (Additional file  12: Figure 
S8).
Influence of low and high diversity transmission
Low diversity transmitters are expected to harbor 
viruses that are phenotypically more closely related to 
the recipient viruses than transmitter viruses with high 
diversity from chronic infection. In our study four trans-
mitters with low virus diversity (env diversity < 1 %) were 
included (T5, T6, T7 and T8). Due to their high sequence 
similarity with the recipient these cases are intriguing 
to study as they may allow to pinpoint domains that are 
under specific selection more accurately. On reverse, 
if adaptation in the transmitters was too short to allow 
adaptation to the new host, these acute transmissions 
may indeed be solely stochastic events and selection only 
evident in chronic transmission. To verify the impact of 
env diversity in the transmitters we analyzed all data sets 
for all nine transmission pairs combined and in a sepa-
rate analysis focusing only on either high or low diversity 
transmission pairs using different thresholds (Additional 
file 13: Table S5). In line with what we observed for the 
combined nine pairs, we detected no consistent pheno-
typic difference of recipient viruses when focusing exclu-
sively on the high diversity transmission pairs or on the 
low diversity transmission cases (Additional file 13: Table 
S5).
Discussion
Discoveries of recent years established that commonly 
only a single viral variant out of a genetically diverse virus 
population in the transmitting partner establishes HIV-1 
infection in the new host [11–15, 39]. It is evident from 
Fig. 6 Transmitter and recipient viruses have comparable cell–cell transmission and free virus infection capacities. a Cell–cell transmission and b 
free virus infection of transmitter (red) and recipient (blue) Env-pseudoviruses are shown. For cell–cell transmission pseudovirus transfected 293-T 
cells (gaussia luciferase reporter NLinGluc) and for free virus infection 293-T derived pseudovirus (firefly luciferase reporter NLluc-AM) were used. 
A3.01-CCR5 served as target cells. Mean and standard deviation from three to six experiments each performed in triplicates are shown. Statistical 
significance between transmitter virus median values and recipient viruses was tested with a Wilcoxon matched-pairs signed rank test
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this that HIV-1 faces a strong population bottleneck 
upon transmission and available data suggest that this 
is most stringent during heterosexual female-to-male 
transmission [48]. To what extent the transmission pro-
cess selects for viruses with specific properties or is sim-
ply the result of a stochastic process has not been fully 
resolved (reviewed in [6, 7]). Several viral features have 
been implicated with transmission success, such as CCR5 
tropism [1, 8–11, 20], a loss of glycosylation sites and a 
reduction in length of variable loops [16–18, 22, 23], a 
higher resistance to IFNα [34, 35] and increased Env 
incorporation [34]. However, to date no consistent pic-
ture has emerged if and which of these viral properties 
are decisive in determining the selection of viral variants 
during mucosal transmission.
Delineating HIV-1 transmission is inherently difficult 
as the earliest events of transmission cannot be cap-
tured and only a limited number of confirmed trans-
mission pairs have been identified. Much of the current 
knowledge is thus based on cross-sectional studies of 
T/F viruses in comparison with unrelated chronic con-
trol viruses. Nevertheless, these cross-sectional studies 
defined virus properties associated with transmission 
despite the high genetic diversity of unrelated virus 
strains. In linked transmission pairs differential prop-
erties should therefore be even more pronounced and 
potentially easier to define which prompted us to per-
form the current study. Transmitter and recipient viruses 
in our study represented the respective circulating virus 
as determined by SGA analysis and the viruses from the 
transmission pairs were closely related based on both env 
and pol sequence analyses. All transmission pairs were 
confirmed based on clinical data, patient demographics, 
self-reporting of exposure and EDT determined based 
on laboratory data. Our paired analysis of transmitters 
and recipients included nine subtype B MSM and MTF 
transmission pairs. Recipient viruses proofed resistant 
to plasma antibodies circulating in the corresponding 
transmitter at the time of transmission underlining that 
a neutralization escape variant was transmitted. Our data 
support findings in subtype B MSM [19] and subtype A, 
C and D mother-to-child transmission [54–56], where no 
selection for neutralization sensitive viruses occurred. 
Although transmission of neutralization sensitive viruses 
may be possible as shown for heterosexual subtype C 
transmission pairs [16, 26], our data support the notion 
that selection for neutralization sensitive variants cannot 
be a general determinant of mucosal HIV-1 transmission.
Since the transmission partners’ immune responses 
are subject to viral escape, resistance to the autologous 
response does not allow conclusions on the general neu-
tralization sensitivity of the virus strains. Previous reports 
in the literature remained inconclusive on whether T/F 
viruses have distinct neutralization properties [11, 20, 24, 
25]. Our comprehensive neutralization sensitivity tests 
with a panel of gp120, gp41 and cell directed antibodies 
and inhibitors revealed, however, no difference in neu-
tralization sensitivity of recipient and transmitter viruses.
Detailed sequence comparison of the env gene of trans-
mitters and recipients also uncovered no consistent dif-
ferences in variable loop length and glycosylation. As 
expected, transmitter sequences were more heterogene-
ous with regard to length and PNGS in the V1V2 and V4 
regions, particularly in chronic transmitters. There was, 
however, no prioritization amongst recipients for shorter 
variable loops or lower glycosylation in accordance with 
previous findings for subtype B transmission [17, 19–21].
Furthermore, we could not identify a difference in the 
conservation of the tripeptide motif responsible for α4β7 
integrin binding between recipients and transmitters. 
Fig. 7 Recipient viruses exhibit a higher sensitivity to IFNα. a Profile of p24 antigen production measured in culture supernatants of CD8-depleted 
PBMCs infected with virus isolates of transmission pair T6–R6 at three different input TCID50’s of 80, 160 or 320. The solid line represents replication 
in absence and the dashed line replication in presence of 1000 U/ml IFNα, respectively. b IFNα resistance defined as area under the curve (AUC) of 
p24 antigen production over a 13 day period for transmitter and recipient virus isolates on PBMCs in the presence of 1000 U/ml IFNα expressed as 
% of AUC in its absence. Four independent experiments indicated by different symbols are depicted. c Median IFNα resistance of four experiments 
between transmitter and recipient viruses was probed with a Wilcoxon matched-pairs signed rank test. Data for transmitters and recipients are 
indicated in red and blue, respectively
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This does however not exclude that differences in expo-
sure of the tripeptide motif may exist that only functional 
assays that assess α4β7 integrin binding or replication in 
α4β7 expressing cells may reveal [32, 57].
In six out of nine transmission pairs recipient Envs 
showed shorter distances to the MRCA when compared 
to transmitters as previously suggested [18, 48], yet this 
difference was not statistically significant. Supporting 
this, across all phenotypic and genotypic parameters 
we assessed recipient viruses closer to the MRCA were 
indistinguishable from transmitters (Additional file  13: 
Table S5).
A detailed analysis of the entry fitness of the transmit-
ter and recipient viruses further highlighted that there is 
no general trend towards selection of viruses with spe-
cific entry properties. In the cases studied, transmission 
did not favor viruses with faster entry kinetics which is in 
agreement with a previous cross-sectional study of HIV-1 
subtype B viruses [20]. Furthermore, recipient viruses 
were also indistinguishable from transmitter viruses in 
their cell–cell transmission or free virus infection capaci-
ties. Likewise we observed no general trend towards 
selection of viruses with higher replicative capacity on 
primary cells (PBMCs and MDMs) again supporting ear-
lier findings [20, 24, 26, 28]. In contrast, a recent study by 
Carlson and colleagues found in a sequence based mod-
elling study of 137 linked heterosexual transmission pairs 
that transmission of more consensus-like variants pre-
dicted increased in vivo fitness in the new host [48].
While most of the features we studied focused solely 
on the impact of the env gene in transmission, the repli-
cative capacity of primary isolates will also be influenced 
by other factors including the efficacy of the reverse 
transcription and integration process or the virus’ capac-
ity to counteract intrinsic defense mechanisms of the 
host cell. The latter has gained particular attention in 
the transmission setting following reports that suggested 
that recipient viruses are more resistant to the action of 
IFNα [34, 35]. Improved evasion of the intrinsic immune 
defense certainly can be envisaged to provide a selec-
tion advantage. When we probed the sensitivity to IFNα 
across our transmission pairs, we observed however no 
such trend. On the contrary, while sensitivities on the 
individual level differed, across all patients recipient 
viruses proved more sensitive to IFNα than transmit-
ter viruses. As IFNα mediated control of HIV-1 is not 
very potent and influenced by subtle differences in virus 
input and replicative capacity, we chose assay conditions 
that ensure that our data on IFNα sensitivity is not con-
founded by differences in replication. It is important to 
note that earlier studies which observed a higher resist-
ance of recipient viruses to IFNα, did not have the pos-
sibility to investigate matched transmission pairs which 
could in part influence conclusions as individual sensi-
tivities can vary substantially [34, 35]. Supporting our 
finding, a recent publication investigating six HIV-1 
subtype C transmission pairs also observed no increased 
resistance of T/F viruses [26]. Furthermore, Etemad and 
colleagues found in injection drug users of HIV-1 sub-
type B an increased IFNα sensitivity of acute Envs as 
compared to chronic Envs [36].
The differences in IFNα sensitivity we observed 
between transmitters and recipients were not pro-
nounced. We thus interpret the fact that recipient viruses 
were more sensitive to IFNα not as a result of positive 
selection of these viruses but rather as an indication that 
the IFN response may not play a critical role during the 
earliest stages of infection leading to the establishment 
of the T/F viruses. That notwithstanding, IFN responses 
certainly play a crucial role in established infection as 
evidenced by the increasing number of antiviral factors 
that are regulated by the type I IFN response (reviewed in 
[58]). In vivo transcriptome studies have shown increased 
IFN expression in patients with high viral loads [59] pro-
posing that escape from IFN triggered restriction factors 
may occur during the course of infection as suggested 
in HIV/Hepatitis C virus co-infected patients following 
treatment with pegylated IFNα/ribavirin [60, 61]. Due to 
the persistent exposure of viruses to IFN, resistant viral 
variants may evolve and the virus population in transmit-
ters likely reflects a very heterogeneous population in this 
respect. Depending on which viral gene is affected by the 
escape to restriction factors this may also impact on the 
viral fitness and provide a selection disadvantage in an 
environment where IFN activation has not yet occurred.
We used low-passage virus isolates to study pheno-
typic properties over multiple rounds of replication, 
namely infection of PBMCs and MDMs as well as sensi-
tivity to IFNα during infection of PBMCs. While the use 
of virus isolates does not allow the focus on a specific 
gene or virus variant, as the fidelity of all virus genes will 
impact infectivity and a range of variants will be present 
in a given stock, this variety also provides opportunities 
for analysis. In addition virus isolates provide insight on 
the replication competent virus population circulating 
in a patient at a given time point. As a main interest of 
our study was on the env gene, we sequenced env genes 
of all virus isolates and found them to closely match the 
defined clonal variants of the respective patients (Addi-
tional file 4: Figure S4) further validating the use of these 
isolates in infectivity experiments. Full-length genome 
constructs as compared to virus isolates may be a use-
ful tool to closely associate genotypes to phenotypes and 
to detect subtle differences more precisely. However, 
selecting IMCs that represent the diversity present in the 
transmitter remains challenging.
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We identified five transmission pairs where transmit-
ters harbored a high virus diversity (env diversity > 1 %) 
and four with low diversity (<1 %) that occurred in trans-
mission during acute phase or early after drug cessation. 
As the latter scenarios are a main source of virus trans-
mission [42–44], we thought it prudent to include the 
low diversity pairs in our analysis. Analyzing both high 
and low diversity transmission pairs may open advanced 
possibilities to trace potential bottlenecks. While in gen-
eral selection may be easier to define in high diversity 
pairs, defining the important genotypic changes associ-
ated with the phenotypic profiles may benefit from analy-
sis in the low diversity setting. We thus performed two 
separate analyses, one for all pairs grouped together and 
one for only high diversity transmission pairs. Similar 
to the observation with all nine transmission pairs, we 
found amongst high diversity pairs no phenotypic prop-
erty that segregated transmitter from recipient viruses. 
As with most other studies in the field, the number of 
transmission pairs identified was small reducing statisti-
cal power to make definite conclusions. Yet, the fact that 
we saw no strong patterns suggests that if during trans-
mission selective forces are present, they are likely to be 
subtle hence will require larger cohorts of transmission 
pairs than currently available to further unravel selective 
properties during transmission.
In sum, with the possible exception of increased sensi-
tivity to IFNα, our study revealed no phenotypic feature 
that was linked with transmission strongly suggesting 
that transmission is to a large proportion stochastic. 
Nevertheless, this does not rule out that selective deter-
minants exist. We consider it thus highly important that 
larger studies are conducted to further explore potential 
factors involved in transmission. These factors may vary 
in type and extent of influence depending on the HIV-1 
subtype, mode of transmission and infection status of the 
transmitter and hence large cohorts of confirmed linked 
transmission pairs that cover all these settings need to be 
established and their viral properties explored. Our study 
further highlights the complexity of the T/F analysis and 
the need for meta studies incorporating published trans-
mission pairs to identify T/F reference variants and key 
methods to build on and to eventually clarify the influ-
ence of viral properties in transmission.
Conclusions
HIV-1 transmission is characterized by a constraint in 
the number of viral variants establishing infection. Sev-
eral viral properties including CCR5 tropism, a reduction 
in length and glycosylation of Env variable loops, replica-
tive capacity and resistance to IFNα have been associated 
with selection at the transmission bottleneck. However, 
if and which of these many phenotypic properties truly 
govern transmission has not been conclusively resolved 
as the investigated cohorts often lacked information on 
linked transmission partners, or cohorts differed in the 
transmission mode and the subtype studied. To investi-
gate selective forces of transmission, we identified nine 
HIV-1 subtype B MSM and MTF transmission pairs and 
assessed their genotypic and phenotypic properties of 
transmitter and recipient viruses isolated at closest pos-
sible time points to transmission.
The viral features we investigated include besides an 
extensive sequence analysis neutralization sensitivity, 
replicative capacity in different cell types and sensitiv-
ity to IFNα. Despite this wide repertoire we found with 
the exception of increased IFNα sensitivity, that none of 
the other properties consistently distinguished recipient 
from transmitter HIV-1 subtype B viruses suggesting that 
transmission is to a considerable extent stochastic. Defin-
ing and fine-tuning viral factors that govern transmission 
will thus remain challenging and warrants further inves-
tigations in larger cohorts of confirmed transmission 
pairs.
Methods
Patients
Patients were enrolled in the Zurich Primary HIV Infec-
tion study (ZPHI) and/or the Swiss HIV Cohort Study 
(SHCS). The ZPHI is an observational, non-randomized, 
single center cohort that includes patients with a con-
firmed acute or recent primary HIV-1 infection (www.
clinicaltrials.gov, ID NCT00537966) [37–39]. Patient vis-
its, blood collections and sampling of plasma and PBMCs 
are scheduled every 3  months. The SHCS is a nation-
wide, clinic-based cohort with semiannual visits and 
blood collections enrolling all HIV-infected adults living 
in Switzerland [40]. The SHCS is estimated to include at 
least 53 % of all HIV infections ever diagnosed in Swit-
zerland of whom 79 % were screened for drug resistance 
since 1996 [40, 41]. The ZPHI study and the SHCS have 
extensive biobanks. The estimated date of transmission 
(EDT) was established for every transmission pair by 
the inclusion of clinical and laboratory data from ZPHI 
patients such as known risk situations, appearance of first 
symptoms, earlier negative test results, avidity assays and 
Western blot results as described in detail elsewhere [37, 
38]. Acute and recent infections were defined as a docu-
mented seroconversion within 90 and 180 days after the 
EDT, respectively [37]. Chronic infections were defined 
as a minimum of 180 days since seroconversion. Patient 
characteristics are listed in Table  1. Three transmission 
pairs could be verified clinically because the infected 
partners accompanied the acutely infected patient to the 
clinic and disclosed the transmission history (T5–R5, 
T8–R8 and T9–R9).
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Phylogenetic and sequence analysis
Phylogenetic linkage was assessed between individuals 
enrolled in the ZPHI and the SHCS using all available 
pol gene sequences derived from genotypic drug resist-
ance tests (years 1995–2012) from the Swiss HIV drug 
resistance database. Population-based sequencing of the 
protease and the reverse transcriptase is done by four 
laboratories authorized by the Federal Office of Public 
Health as described previously [62]. We used R software 
environment for statistical computing (http://www.R-
project.org), HMMalign [63], PHYLIP 3.68 (distributed 
by J. Felsenstein, University of Washington, Seattle) and 
a collection of Unix shell scripts and Perl scripts. Sub-
sequently, therapy history, viral load time courses and 
the EDT were used to verify a potential transmission 
cluster. From these derived putative transmission pairs, 
confirmatory single genome amplification and sequenc-
ing of full-length env and phylogenetic analysis thereof 
was done. Pairwise genetic distances and viral diversi-
ties were calculated by MEGA5 using the Tamura-Nei 
model [64]. Neighbor joining phylogenetic trees were 
constructed with MEGA5 using the bootstrap method 
(1000 replications). Maximum likelihood phylogenetic 
trees were inferred with Dnaml (PHYLIP 3.68) using 
randomized input order, global rearrangements and mul-
tiple jumble options. For construction of phylogenetic 
trees following HIV-1 subtype reference sequences were 
used: B [GenBank:K03455], A1 [GenBank:AF004885], D 
[GenBank:K03454], C [GenBank:U52953] and F1 [Gen-
Bank: AF077336]. V1V2 and V4 domains were assigned 
for each sequence relative to HXB2 (HIV sequence com-
pendium 2014). PNGS in V1V2 and V4 were determined 
using Glycosite (www.hiv.lanl.gov). Highlighter plots 
were generated with Highlighter for Amino Acids v1.3.4 
(www.hiv.lanl.gov). The between group mean distance of 
transmitter and recipient env sequences to the MRCA 
sequence was calculated in MEGA5 using the Tamura-
Nei model.
Single genome amplification and sequencing
Single genome amplification and sequencing were 
performed according to previously described proto-
cols [65]. Briefly, viral RNA was extracted from plasma 
using the RNeasy Kit (Qiagen) and reverse transcribed 
to cDNA using Superscript III (Life Technologies) and 
primer MascN (5′-CTGCCAATCAGGGAAGTAGCC 
TTGTGT-3′). To get an approximation of the quantity, 
cDNA was subjected to real-time PCR analysis. Subse-
quently, the cDNA was diluted to the endpoint so that 
no more than 30 % of the wells were PCR product posi-
tive. Two sequential PCR amplification reactions covering 
full-length env (nucleotides 6183–9096 based on HIV-1 
HXB2) were then performed with Platinum Taq High 
Fidelity Polymerase (Life Technologies) according to the 
manufacturer’s instructions. Outer primers were MascA 
(5′-CACCGGCTTAGGCATCTCCTATGGCAGGAAG 
AA-3′) and MascN. The first PCR product was diluted 
10 times for the second PCR. Primers for the nested 
second PCR were Ri29 (5′-GGTTAATTGATAGA 
CTAATAGAAAGAGCAG-3′) and MascM (5′-TAG 
CCCTTCCAGTCCCCCCTTTTCTTTTA-3′). The PCR 
cycle conditions for both amplifications were: 94  °C for 
2  min followed by 35 cycles of 94  °C for 15  s, 55  °C for 
30 s, and 68 °C for 4 min, followed by a final extension at 
68  °C for 10 min. PCR amplicons were gel purified with 
the QIAquick gel extraction kit (Qiagen) before sequenc-
ing. Full-length single genome sequences were derived by 
merging bidirectional sequences of 10 overlapping regions 
generated by dye terminator cycle sequencing (ABI Prism 
BigDye, Applied Biosystems). Sequences were edited with 
SeqMan (DNASTAR Inc., Wisconsin, USA) and checked 
for reading errors, premature stop codons and hypermu-
tations with Hypermut (www.hiv.lanl.gov).
Cells
293-T cells were obtained from the American Type Cul-
ture Collection (ATCC). TZM-bl and MT-2 cells were 
obtained from the NIH AIDS Reagent Program (NIH 
ARP). A3.01-CCR5 cells were described previously [66]. 
293-T and TZM-bl cell lines were cultivated in DMEM 
containing 10 % heat-inactivated FCS and 1 % penicillin/
streptomycin (P/S). MT-2 and A3.01-CCR5 cells were 
cultivated in RPMI 1640 containing 10 % heat-inactivated 
FCS and 1 % P/S. For TZM-bl infection experiments cell 
culture medium was supplemented with 10 μg/ml dieth-
ylaminoethyl-dextran (DEAE-dextran).
Stimulated primary CD8-depleted PBMCs were pre-
pared as described [67]. Briefly, buffy coats from three 
healthy blood donors were CD8+ T cell depleted and 
PBMCs were isolated. Cells were adjusted to 4 × 106 per 
ml with RPMI 1640 containing 10  % heat-inactivated 
FCS, 10 U/ml IL-2 and 1 % P/S, divided into three por-
tions and stimulated with either 5  μg/ml phytohemag-
glutinin, 0.5  μg/ml phytohemagglutinin or OKT3. After 
48  h, cells from all three stimulations were pooled and 
cultivated in RPMI 1640 containing 10 % heat-inactivated 
FCS, 50 U/ml IL-2 and 1 % P/S for further experiments.
To generate MDMs, CD14+ monocytes were isolated 
from CD8+ T-cell depleted PBMCs using CD14-coated 
magnetic microbeads (Miltenyi Biotec). Purity was 
checked by flow cytometry and monocytes were cultured 
in a 96-well plate at a density of 7 × 104 per well in RPMI 
1640 medium containing 10 % human serum (Sigma), 1 % 
P/S and 20 ng/ml macrophage colony-stimulating factor 
(M-CSF) (Peprotech). After 6 days, media was changed to 
RPMI 1640 containing 5 % human serum and 1 % P/S.
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Reagents
We thank following individuals for kindly providing anti-
bodies or antibody expression plasmids: D. Burton, The 
Scripps Research Institute, La Jolla, USA for b12 [68], 
b6 [69], PGT121 and PGT128 [70]; D. Katinger, Poly-
mun Scientific, Vienna, Austria for 2F5 [71], 4E10 [72, 
73] and 2G12 [74]; J. Mascola, NIH, Bethesda, USA for 
VRC01 [75]; M. Nussenzweig, the Rockefeller University, 
New York, USA for 1.79 [76]. Antibody was produced by 
expression in 293-F cells and purified by protein G affin-
ity and size exclusion chromatography [77]. DARPin 27.2 
was produced as described [78]. CD4-IgG2 was pro-
vided by Progenics Pharmaceuticals. T-20 and Maraviroc 
were purchased from Roche Pharmaceuticals and Pfizer, 
respectively.
Viruses
Autologous virus was isolated by co-culturing patient 
CD4+ T cells with stimulated, CD8-depleted PBMCs. 
The TCID50 on PBMCs and the co-receptor usage on 
MT-2 cells of the obtained virus isolates were determined 
as described previously [79].
For the generation of Env-pseudoviruses, viral RNA 
from plasma or virus isolates was isolated using the Rne-
asy kit (Qiagen) and reverse transcribed into cDNA using 
Superscript III (Life Technologies) and primer MascN. 
Subsequently, full-length env (nucleotides 5978–9171 
based on HXB2) was PCR amplified with Platinum Taq 
High Fidelity Polymerase (Life Technologies) according 
to the manufacturer’s instructions. Primers for amplifi-
cation were 5′allspl (5′-AAGAAGCGGAGACAGCGA 
CGAAGA-3′) and MascN. The PCR cycle conditions 
were: 94 °C for 2 min followed by 35 cycles of 94 °C for 
30 s, 58 °C for 30 s, and 68 °C for 3.5 min, followed by a 
final extension at 68 °C for 10 min. PCR products were gel 
purified and cloned into the pcDNA3.1/V5-His-TOPO 
expression vector (Life Technologies). Transformation 
into E. coli XL10 Gold (Agilent) was done according to 
the manufacturer’s instructions. Control of plasmid 
insert orientation via env PCR, plasmid preparation, 
Env-pseudovirus generation in small scale for function-
ality test and subsequent functionality screen on TZM-
bl cells were performed as described [80]. Furthermore, 
clones were sequenced by Illumina MiSeq. For large scale 
Env-pseudovirus production, T75 cell culture flasks with 
293-T cells were co-transfected with an HIV-1 backbone 
plasmid carrying the luciferase reporter gene (pNLluc-
AM, [77]) and the respective env plasmid at a ratio of 
3:1 using polyethylenimine (PEI) as described [81]. 48 h 
after transfection, virus supernatant was harvested and 
filtered. The infectivity of serial dilutions of pseudovirus 
stocks expressing the different Envs was determined on 
TZM-bl cells and the activity of the luciferase reporter 
was recorded in relative light units (RLU) per μl of virus 
stock.
Illumina next generation sequencing
Env plasmids were sequenced with the Illumina MiSeq 
v2 50 cycles kit. For preprocessing and de novo assem-
bly, CLC Genomics Server version 6.5 trim and map-
ping algorithms were used to trim 23 nucleotides from 
the 5′ and 3′ ends, followed by end quality trimming to 
obtain reads with an average Phred score >30 and free 
of ambiguous nucleotides. Contigs were generated using 
the de novo assembly algorithm with automatic bubble 
and word size parameters specified. HIV-1 contigs were 
then positively selected by aligning them to the HXB2 
reference.
Patient plasma or primary virus isolates were 
sequenced with the Illumina MiSeq v2 300, 500 or 600 
cycles kit. Reads were pre-processed using prinseq-lite.
pl [82]. Prinseq-lite.pl allowed for quality trimming and 
removal of reads with an average Phred score <30 and 
ambiguous nucleotides. Overlapping read pairs were 
merged using Flash [83]. Alignments were generated 
using the Burrows-Wheeler Aligner BWA mem algo-
rithm [84] with individual specific gp120 references. Indi-
vidual specific gp120 references were derived by aligning 
the following to the Los Alamos HIV-1 HXB2 subtype B 
reference: (1) contigs obtained from de novo assembly—
using the methods mentioned above; and (2) sample spe-
cific consensus sequences—called from CLC Genomic 
Workbench Extract Consensus Sequence algorithm for 
BWA mem alignments of sample specific reads (plasma 
or primary virus isolate) to a Zurich HIV-1 subtype B 
reference, with “Threshold  =  100” and “Post-remove 
action = Split into separate sequences” specified. Haplo-
types were generated for gp120 using QuasiRecomb [85] 
with the—conservative and—K 1-100 options specified. 
Haplotypes with frequencies >1 % and a Phred score >30 
were retained for subsequent analysis.
In vitro replicative capacity
To assess the in  vitro replicative capacity on PBMCs, 
virus isolates were serially diluted in cell culture medium 
and 100  μl virus dilution was added in quadruplicates 
per dilution on 96-well plates containing 2 ×  105 stim-
ulated CD8-depleted PBMCs in 100  μl culture medium 
per well. 50 μl culture supernatants were harvested and 
50 μl fresh medium was added back on days 4, 5, 6, 7, 8, 
10, 12 and 14 post infection (p.i.). At day 14 p.i. culture 
supernatants were assayed for p24 antigen by using an in-
house p24 antigen enzyme-linked immunosorbent assay 
(ELISA) as described previously [86, 87] and the TCID50 
was determined. Retrospectively, p24 antigen was meas-
ured by ELISA of the dilution containing the same virus 
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inoculum (125 TCID50 per well as determined with day 
14 p.i. supernatants of the same experiment) from all 
other harvesting days. Because the virus inoculum was 
not washed out after infection, the residual input p24 
concentration was measured and subtracted from all test 
results.
To assess the in  vitro replicative capacity on MDMs, 
8  days after monocyte isolation 96-well plates contain-
ing 7 ×  104 MDMs per well were infected in triplicates 
with virus isolates at an MOI of 0.05, spinoculated onto 
MDMs (1200  g, 120′) and unbound virus was washed 
away. On day 1, 7 and 14 p.i. 50  μl culture supernatant 
was assayed for p24 antigen by ELISA.
To assess the in  vitro replicative capacity in the pres-
ence of IFNα, 96-well plates containing 2 ×  105 stimu-
lated CD8-depleted PBMCs in 100  μl of cell culture 
medium were pre-treated with 1000  U/ml of IFNα-2a 
(Roferon-A, Roche Pharmaceuticals) for 4  h at 37  °C. 
Virus isolates were then added at a TCID50 of 80 per well 
(as determined on the same pool of stimulated CD8-
depleted PBMCs) in 100  μl cell culture medium to 6 
wells of IFNα-2a treated and 6 wells of untreated PBMCs. 
Virus inoculum was washed out on day 1 p.i. Culture 
supernatants were harvested, assayed for p24 antigen by 
ELISA and culture wells fed with new medium on days 
1, 3, 5, 7, 9, 11 and 13 p.i. In addition, on every day until 
day 8 (after that no new infection of PBMCs occurs) new 
IFNα-2a was added onto the culture wells. In this manner 
a final assay concentration of 1000 U/ml was maintained 
in the culture wells throughout the experiment as IFNα is 
known to have a short half-life.
As a measure of replicative capacity, we determined the 
AUC of the p24 production in ng/ml with following for-
mula: AUC =  (p242 −  p241)  *  (T2 −  T1)/ln(p242/p241). 
The sum of AUCs from successive time points then gave 
the total AUC.
Neutralization assays
The neutralization activity of entry inhibitors and patient 
plasma against transmitter and recipient Env-pseudovi-
ruses was evaluated in single-round infection assays 
using TZM-bl cells as described [81]. TZM-bl cells were 
seeded in 96-well plates (10,000 cells per well). Virus 
inoculum was chosen to yield an infectivity of 5000–
20,000 RLU/well in the absence of inhibitors or plasma.
Pseudoviruses carrying the murine leukemia virus and 
the HIV-1 SF162 Envs were used as negative and positive 
controls for all plasma samples, respectively. The inhibi-
tor concentration or reciprocal plasma dilution causing 
50  % reduction in viral infectivity (IC50 or NT50) were 
derived by fitting pooled data from 2 independent experi-
ments to the log inhibitor vs. response variable slope fit 
in GraphPad Prism. The MPN was defined as the average 
percent neutralization reached at the highest plasma 
concentration of 1:40. If 50  % inhibition or neutraliza-
tion was not reached at the highest or lowest inhibitor or 
plasma concentration, a greater-than or less-than value 
was recorded and used for statistical tests.
Entry kinetics assays
Entry kinetics was probed as previously described [51]. 
Briefly, TZM-bl cells were seeded in 96-well plates 
(20,000 cells per well). Env-pseudovirus stocks adjusted 
to 50,000 RLU in 100 μl culture medium were added per 
well and spinoculated for 70′ at 1200  g and 10  °C onto 
TZM-bl cells. Unbound virus was removed and infection 
was rendered permissive by addition of media warmed to 
37 °C. Subsequently, the inhibitor T-20 was added in sat-
urating concentrations (final assay concentration: 50 μg/
ml) at defined time points post infection to block viral 
entry. 48  h after infection, the production of luciferase 
was quantified. The T-20 addition after 120′ value was set 
as 100 % and all other T-20 addition wells were normal-
ized to it. The time until 50 % of virus entry was derived 
from entry kinetic curves.
Cell–cell transmission and free virus infection
Cell–cell transmission and free virus infection was tested 
as described [52, 53]. 293-T cells were seeded in 12-well 
plates (1  ×  105 cells per well) and transfected with the 
env plasmids and the NLinGluc vector [88, 89] for cell–
cell transmission or the NLluc-AM vector for free virus 
infection at a ratio of 1:3 using PEI.
To assess cell–cell transmission, 6 h after transfection the 
supernatant was removed and the 293-T cells were resus-
pended in 2 ml culture medium (without DEAE-dextran). 
5 × 103 transfected cells were seeded to 1.5 × 104 A3.01-
CCR5 cells per well (in triplicates per env plasmid). After 
65 h incubation at 37 °C gaussia luciferase production was 
quantified (Renilla Luciferase Assay system, Promega).
To assess free virus transmission, 6  h after transfec-
tion the supernatant was replaced with 1  ml fresh cul-
ture medium. 48 h later, the virus-containing supernatant 
was harvested, cleared by centrifugation and stored at 
−80 °C. Subsequently, 50 μl virus was added onto 5 × 104 
A3.01-CCR5 cells per well in 96-well plates (in triplicates 
per env plasmid) in the presence of 10 μg/ml DEAE-dex-
tran. After 65 h incubation at 37 °C firefly luciferase pro-
duction was quantified.
Statistical analysis
All statistical analyses were performed in GraphPad 
Prism 5 (GraphPad Software). Transmitter and recipient 
viruses were compared by the Wilcoxon matched-pairs 
signed rank test. When more than one Env-pseudovirus 
was measured per patient, the median value was taken 
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for statistical tests. Correlation was performed by linear 
regression analysis. p value ≤0.05 was considered statisti-
cally significant.
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as a subtype B reference.
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aligned to it. Amino acid mismatches are illustrated by a colored bar. 
Sequences are derived from single genome amplification (SGA_X), clon-
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and plasma virus. Note that haplotypes for primary virus isolates and 
plasma are only spanning gp120 and only those at a frequency above 
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transmitter (red) and recipient (blue) Env-pseudoviruses by transmitter 
plasma from the closest time point to the EDT at the highest plasma 
concentration tested of 1:40. Line indicates 50 % neutralization and dif-
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ness were compared between transmitter and recipient virus isolates. (a) 
Median area under the curve (AUC) until day 7. (b) Median absolute p24 
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